Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Cash from Operations (2022 - 2025)

BioXcel Therapeutics has reported Cash from Operations over the past 4 years, most recently at 14210000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 14210000.0 for Q4 2025, up 4.04% from a year ago — trailing twelve months through Dec 2025 was 57615000.0 (up 20.01% YoY), and the annual figure for FY2025 was 57615000.0, up 20.01%.
  • Cash from Operations for Q4 2025 was 14210000.0 at BioXcel Therapeutics, up from 18787000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for BTAI hit a ceiling of 12043000.0 in Q1 2025 and a floor of 52353000.0 in Q1 2023.
  • Median Cash from Operations over the past 4 years was 25018500.0 (2023), compared with a mean of 26249312.5.
  • Biggest five-year swings in Cash from Operations: crashed 61.52% in 2023 and later soared 66.18% in 2024.
  • BioXcel Therapeutics' Cash from Operations stood at 38639000.0 in 2022, then skyrocketed by 30.48% to 26863000.0 in 2023, then skyrocketed by 44.87% to 14809000.0 in 2024, then rose by 4.04% to 14210000.0 in 2025.
  • The last three reported values for Cash from Operations were 14210000.0 (Q4 2025), 18787000.0 (Q3 2025), and 12575000.0 (Q2 2025) per Business Quant data.